News
Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
1d
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback